Guanethidine |
| Catalog No.GC66202 |
구아네티딘 황산염은 1959년에 합성되었습니다. 구아네티딘은 혈압을 낮추는 것으로 생각됩니다\r\n 821d96072c2d58d8970e76f526b0f6b8신경절후 교감 신경 섬유에서 화학적 전달 물질의 대사를 방해함으로써.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55-65-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure
by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Ablation of sympathetic fibers is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro[1].
.
Guanethidine (30 mg/kg, s.c., 1 h) unaffected IL-18 hypernociception in TNFR1(-/-) mice as a sympathetic blocker[2].
.
| Animal Model: | Wild-type (WT) Balb/c,TNFR1(-/-)and IFN-γ-γ(-/-) mice[2]. |
| Dosage: | 30 mg/kg |
| Administration: | Guanethidine (30 mg/kg, s.c., 1 h, diluted in saline) |
| Result: | Pre-treatment with guanethidine (sympathetic blocker) unaffected IL-18 hypernociception in TNFR1(-/-) mice. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *